https://www.openbell.ai/ 2026-10-12T11:42:50.052Z hourly 1.0 https://www.openbell.ai/support 2026-10-12T11:42:50.052Z monthly 0.7 https://www.openbell.ai/privacy 2026-10-12T11:42:50.052Z monthly 0.5 https://www.openbell.ai/terms 2026-10-12T11:42:50.052Z monthly 0.5 https://www.openbell.ai/feed.json 2026-10-12T11:42:50.052Z hourly 0.8 https://www.openbell.ai/news/STNG:1791805231027 2026-10-12T11:40:31.027Z daily 0.9 https://cdn.brandfetch.io/STNG/w/400/h/400?c=1idopYfmtR7ZKg8QMud Reported Earlier, 'Oil Tanker Rates Surge Amid Rising Attacks, Longer Voyages' - WSJ Oil tanker rates have surged due to increasing attacks and longer voyages, impacting the shipping industry. This trend comes amid concerns over global fuel shortages, with oil prices fluctuating as markets react to potential increases in Russian diesel supply. The situation is likely to affect companies in the sector, including STNG, as they navigate these challenges. https://www.openbell.ai/news/THFF:1791805192597 2026-10-12T11:39:52.597Z daily 0.9 https://cdn.brandfetch.io/THFF/w/400/h/400?c=1idopYfmtR7ZKg8QMud Hovde Group Initiates Coverage On First Financial with Outperform Rating, Announces Price Target of $85 Hovde Group has initiated coverage on First Financial (NASDAQ: THFF) with an Outperform rating. The analyst, Brendan Nosal, has set a price target of $85 for the stock. https://www.openbell.ai/news/CRWD:1791805189486 2026-10-12T11:39:49.486Z daily 0.9 https://cdn.brandfetch.io/CRWD/w/400/h/400?c=1idopYfmtR7ZKg8QMud Why Is CrowdStrike Stock Gaining Monday? CrowdStrike Holdings Inc. (NASDAQ: CRWD) stock is rising in premarket trading, gaining 0.71% to $277.00, following a two-day decline. Analyst Mike Cikos from Needham maintained a Buy rating and raised the price target from $250 to $310, citing the demand for the Falcon Flex offering and the potential of Next-Gen SIEM as growth drivers. Cikos estimates revenue could reach $6.0 billion in 2027 and $7.36 billion in 2028, representing year-over-year growth of 24.8% and 22.5%, respectively. Additionally, CrowdStrike advised shareholders to reject a mini-tender offer from Tutanota LLC for 500,000 shares at $260 each, highlighting concerns over the offer's conditions. https://www.openbell.ai/news/CRBG:1791805169849 2026-10-12T11:39:29.849Z daily 0.9 https://cdn.brandfetch.io/CRBG/w/400/h/400?c=1idopYfmtR7ZKg8QMud Piper Sandler Maintains Overweight on Corebridge Financial, Raises Price Target to $40 Piper Sandler analyst Paul Newsome has maintained an Overweight rating on Corebridge Financial (NYSE: CRBG) and raised the price target from $38 to $40. This indicates a positive outlook for the company's stock performance. https://www.openbell.ai/news/JAZZ:1791805167506 2026-10-12T11:39:27.506Z daily 0.9 https://cdn.brandfetch.io/JAZZ/w/400/h/400?c=1idopYfmtR7ZKg8QMud Jim Cramer Gives Green Light To This Health Care Stock Jim Cramer advised against investing in Apple Hospitality REIT (NYSE: APLE) due to rising interest rates, suggesting potential losses. He expressed a preference for Jazz Pharmaceuticals (NASDAQ: JAZZ), which RBC Capital maintains an Outperform rating on, although the price target was slightly reduced from $299 to $296. Cramer also noted a recent spin-off of Corteva's seed and genetics business into Vylor (NYSE: VYLR) and mentioned EchoStar (NASDAQ: ECHO) as a potential acquisition target for SpaceX. On the market front, Corteva shares fell 3.7%, while Onto Innovation shares rose 0.6% and Jazz Pharmaceuticals dropped 1.8%. https://www.openbell.ai/news/ENVX:1791805058010 2026-10-12T11:37:38.010Z daily 0.9 https://cdn.brandfetch.io/ENVX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Enovix Reports Q3 Preliminary Revenue Of $11M, Up 38% YoY Enovix Corporation (Nasdaq: ENVX) reported preliminary Q3'26 revenue of $11 million, representing a 38% increase year-over-year and exceeding their guidance of $9 million to $10 million. This marks the company's sixth consecutive quarter of year-over-year revenue growth. Additionally, Enovix announced a leadership realignment. https://www.openbell.ai/news/CRVO:1791805016031 2026-10-12T11:36:56.031Z daily 0.9 https://cdn.brandfetch.io/CRVO/w/400/h/400?c=1idopYfmtR7ZKg8QMud CervoMed Announces Data From Its Phase 2a Clinical Study Of Nonfluent Variant Primary Progressive Aphasia Shows Reduction In Mean Plasma Levels Of Neurofilament Light Chain CervoMed Inc. (NASDAQ: CRVO) reported initial data from its Phase 2a clinical trial indicating a reduction in mean plasma levels of neurofilament light chain (NfL) after 12 weeks of treatment with neflamapimod for nonfluent variant primary progressive aphasia (nfvPPA). The results were presented at the 15th International Society of Frontotemporal Dementias Annual Meeting in Philadelphia. https://www.openbell.ai/news/KOD:1791804977959 2026-10-12T11:36:17.959Z daily 0.9 https://cdn.brandfetch.io/KOD/w/400/h/400?c=1idopYfmtR7ZKg8QMud HC Wainwright & Co. Maintains Buy on Kodiak Sciences, Raises Price Target to $126 HC Wainwright & Co. analyst Matthew Caufield has maintained a 'Buy' rating on Kodiak Sciences (NASDAQ: KOD) and raised the price target from $96 to $126. This adjustment reflects a positive outlook for the company in the market. https://www.openbell.ai/news/MLYS:1791804896462 2026-10-12T11:34:56.462Z daily 0.9 https://cdn.brandfetch.io/MLYS/w/400/h/400?c=1idopYfmtR7ZKg8QMud HC Wainwright & Co. Reiterates Buy on Mineralys Therapeutics, Maintains $56 Price Target HC Wainwright & Co. analyst Matthew Caufield has reiterated a Buy rating on Mineralys Therapeutics (NASDAQ: MLYS) and maintained a price target of $56 for the stock. https://www.openbell.ai/news/PVLA:1791804793690 2026-10-12T11:33:13.690Z daily 0.9 https://cdn.brandfetch.io/PVLA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Palvella Says QTORIN Rapamycin Systemic Exposure At Least 40-Fold Lower Than Published Oral Sirolimus Data In Phase 3 Substudy openbell Financial News https://www.openbell.ai/news/INSM:1791804787650 2026-10-12T11:33:07.650Z daily 0.9 https://cdn.brandfetch.io/INSM/w/400/h/400?c=1idopYfmtR7ZKg8QMud HC Wainwright & Co. Reiterates Buy on Insmed, Announces $220 Price Target HC Wainwright & Co. analyst Andrew S. Fein has reiterated a Buy rating on Insmed (NASDAQ: INSM) and set a price target of $220 for the company's stock. https://www.openbell.ai/news/TGTX:1791804719245 2026-10-12T11:31:59.245Z daily 0.9 https://cdn.brandfetch.io/TGTX/w/400/h/400?c=1idopYfmtR7ZKg8QMud TG Therapeutics Says BRIUMVI Showed 44% Lower Risk Of MS Disability Progression vs. Ocrelizumab, 49% vs. Ofatumumab In Indirect Comparison openbell Financial News https://www.openbell.ai/news/NCNO:1791804718061 2026-10-12T11:31:58.061Z daily 0.9 https://cdn.brandfetch.io/NCNO/w/400/h/400?c=1idopYfmtR7ZKg8QMud nCino Unveils Loan Officer Productivity Suite, Comprehensive Set Of AI-Driven Tools To Boost Mortgage Originator Productivity nCino, Inc. (NASDAQ: NCNO) has launched its Loan Officer Productivity Suite, a set of AI-driven tools aimed at enhancing mortgage originator productivity. This suite integrates features within nCino’s mobile-native point of sale, allowing originators to reduce manual work and focus more on borrower interactions. The tools utilize each institution's data and guidelines to provide tailored, institution-specific answers and actions. https://www.openbell.ai/news/STEX:1791804685608 2026-10-12T11:31:25.608Z daily 0.9 https://cdn.brandfetch.io/STEX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Streamex Announces Availability Of Gold-Backed GLDY Shares Through Community National Bank’s CNB Custody openbell Financial News https://www.openbell.ai/news/CGEN:1791804630979 2026-10-12T11:30:30.979Z daily 0.9 https://cdn.brandfetch.io/CGEN/w/400/h/400?c=1idopYfmtR7ZKg8QMud HC Wainwright & Co. Reiterates Buy on Compugen, Maintains $4 Price Target HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a Buy rating on Compugen (NASDAQ: CGEN) and maintained a price target of $4 for the stock. https://www.openbell.ai/news/SOPH:1791804484468 2026-10-12T11:28:04.468Z daily 0.9 https://cdn.brandfetch.io/SOPH/w/400/h/400?c=1idopYfmtR7ZKg8QMud HC Wainwright & Co. Reiterates Buy on Sophia Genetics, Maintains $14 Price Target HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a Buy rating on Sophia Genetics (NASDAQ: SOPH) and maintained a price target of $14 for the stock. https://www.openbell.ai/news/ABSI:1791804381305 2026-10-12T11:26:21.305Z daily 0.9 https://cdn.brandfetch.io/ABSI/w/400/h/400?c=1idopYfmtR7ZKg8QMud HC Wainwright & Co. Reiterates Buy on Absci, Maintains $16 Price Target HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a Buy rating on Absci (NASDAQ: ABSI) and maintained a price target of $16 for the company's stock. https://www.openbell.ai/news/HUM:1791804358506 2026-10-12T11:25:58.506Z daily 0.9 https://cdn.brandfetch.io/HUM/w/400/h/400?c=1idopYfmtR7ZKg8QMud Raymond James Upgrades Humana to Outperform, Announces $520 Price Target Raymond James analyst John Ransom has upgraded Humana (NYSE: HUM) from Market Perform to Outperform, setting a price target of $520 for the stock. This upgrade indicates a positive outlook for Humana's performance in the market. https://www.openbell.ai/news/MTN:1791804136622 2026-10-12T11:22:16.622Z daily 0.9 https://cdn.brandfetch.io/MTN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Stifel Maintains Buy on Vail Resorts, Raises Price Target to $172 Stifel analyst Jeffrey Stantial has maintained a Buy rating on Vail Resorts (NYSE: MTN) and increased the price target from $157 to $172. This adjustment reflects a positive outlook for the company in the market. https://www.openbell.ai/news/MAT:1791804039501 2026-10-12T11:20:39.501Z daily 0.9 https://cdn.brandfetch.io/MAT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Seaport Global Upgrades Mattel to Buy, Announces $20 Price Target Seaport Global analyst Gerrick Johnson has upgraded Mattel (NASDAQ: MAT) from a Neutral rating to a Buy rating. The firm has set a price target of $20 for the company's stock. https://www.openbell.ai/news/DCX:1791804024507 2026-10-12T11:20:24.507Z daily 0.9 https://cdn.brandfetch.io/DCX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Digital Currency X Technology Enters Investment And Exclusive Commercialization Agreement Whales AI To Advance Commercialization Its AI-Powered STEM Education Robotics Platform In North America; DCX To Provide Initial Investment Of $4M Digital Currency X Technology (DCX) has entered an investment and exclusive commercialization agreement with Whales AI, committing an initial investment of $4 million to advance its AI-powered STEM education robotics platform in North America. Under the agreement, DCX will have exclusive rights to market and sell the platform, with revenue sharing set at 60% for DCX and 40% for Whales AI. Additionally, there is potential for future investments of up to $16 million, contingent on the platform's development and commercialization milestones. https://www.openbell.ai/news/MBX:1791803950555 2026-10-12T11:19:10.555Z daily 0.9 https://cdn.brandfetch.io/MBX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Stifel Maintains Buy on MBX Biosciences, Raises Price Target to $84 Stifel analyst Annabel Samimy has reaffirmed a Buy rating on MBX Biosciences (NASDAQ: MBX) and increased the price target from $70 to $84. This adjustment reflects a positive outlook for the company in the market. https://www.openbell.ai/news/UCO:1791803950510 2026-10-12T11:19:10.510Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/12/US-and-Iran-flags-on-a-cracked-backgroun.jpg?width=250&height=187 Iran Was ‘Taking It Easy’ on Trump, Says Analyst — Fresh Tanker Strikes Near Oman Raise Fears the War Could Trigger a Bigger Oil Shock Brett Erickson, Managing Principal at Obsidian Risk Advisors, indicated that Iran's recent strikes on vessels in the Gulf of Oman could escalate tensions and threaten oil flow, suggesting that the U.S. should reconsider its military strategy. The UKMTO reported that a Marshall Islands-flagged vessel was struck, resulting in two Indian mariners missing and significant damage to the ships involved. Following these incidents, West Texas Intermediate crude futures rose by 1.08% to $92.82, while Brent futures increased by 1.31% to $106.09. https://www.openbell.ai/news/NGEN:1791803876370 2026-10-12T11:17:56.370Z daily 0.9 https://cdn.brandfetch.io/NGEN/w/400/h/400?c=1idopYfmtR7ZKg8QMud NervGen Doses First Participant In Phase 3 RESTORE Study Of NVG-291 For Chronic Cervical SCI; Enrollment Completion Expected In H2 2027, Topline Data In H1 2028 NervGen (NASDAQ: NGEN) has initiated the Phase 3 RESTORE study by dosing its first participant to evaluate NVG-291 for improving hand function and quality of life in chronic cervical motor-incomplete spinal cord injury patients. This study follows positive results from the Phase 1b/2a CONNECT SCI study and has received FDA alignment on its design. Enrollment is expected to be completed in the second half of 2027, with topline data anticipated in the first half of 2028. https://www.openbell.ai/news/JZXN:1791803843477 2026-10-12T11:17:23.477Z daily 0.9 https://cdn.brandfetch.io/JZXN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Jiuzi Holdings Announces Strategic Investor Commitment To Invest At Least $50M In Its Shares At No Less Than $2.50/Share Jiuzi Holdings has announced a strategic investor commitment to invest at least $50 million in its shares, with a minimum price of $2.50 per share. This investment is seen as a sign of confidence in the company's long-term development prospects and aims to enhance its capital resources and financial flexibility. Details regarding the final investment amount, number of shares, and implementation timetable will be disclosed as the transaction arrangements are finalized, subject to necessary approvals and closing conditions. https://www.openbell.ai/news/KE:1791803784497 2026-10-12T11:16:24.497Z daily 0.9 https://cdn.brandfetch.io/KE/w/400/h/400?c=1idopYfmtR7ZKg8QMud Cantor Fitzgerald Suspends Overweight Rating on Kimball Electronics Cantor Fitzgerald has suspended its Overweight rating on Kimball Electronics, which trades under the NASDAQ ticker KE. No specific reasons or financial figures were provided in the announcement. https://www.openbell.ai/news/UBER:1791803618660 2026-10-12T11:13:38.660Z daily 0.9 https://cdn.brandfetch.io/UBER/w/400/h/400?c=1idopYfmtR7ZKg8QMud Cantor Fitzgerald Reiterates Overweight on Uber Technologies, Maintains $90 Price Target Cantor Fitzgerald analyst Deepak Mathivanan has reiterated an Overweight rating on Uber Technologies (NYSE: UBER) and maintained a price target of $90. This endorsement reflects confidence in the company's performance and potential for growth. https://www.openbell.ai/news/HOOD:1791803559763 2026-10-12T11:12:39.763Z daily 0.9 https://cdn.brandfetch.io/HOOD/w/400/h/400?c=1idopYfmtR7ZKg8QMud Evercore ISI Group Initiates Coverage On Robinhood Markets with Outperform Rating, Announces Price Target of $130 Evercore ISI Group has initiated coverage on Robinhood Markets (NASDAQ: HOOD) with an 'Outperform' rating. The firm has set a price target of $130 for the stock. https://www.openbell.ai/news/MCHP:1791803481874 2026-10-12T11:11:21.874Z daily 0.9 https://cdn.brandfetch.io/MCHP/w/400/h/400?c=1idopYfmtR7ZKg8QMud Microchip Technology Expands Portfolio Of Data Center Solutions With New PCIe Connectivity, NVMe Storage And Acceleration Solutions Microchip Technology (NASDAQ: MCHP) is expanding its data center solutions portfolio by introducing new PCIe connectivity, NVMe storage, and acceleration innovations aimed at enhancing high-performance computing infrastructure. The new Switchtec PCIe 6.0 Low-Lane-Count switch offers up to 64 PCIe Gen 6 lanes and various bifurcation options, designed for space- and power-constrained platforms. This advancement includes features such as integrated Direct Memory Access for efficient data movement and enhanced security measures, catering to the growing demand for scalable data center architectures. https://www.openbell.ai/news/XPEV:1791803342568 2026-10-12T11:09:02.568Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/12/XPeng-Inc.jpg?width=250&height=187 Tesla Rival XPeng Says It Can Adapt Driver-Assist Tech for Europe in Just 2 Weeks as Elon Musk's TSLA Faces Fresh Regulatory Pushback Over FSD XPeng Inc. (NYSE: XPEV) announced it can adapt its driver assistance technology to meet European safety standards within two weeks, as the company aims for international expansion. The automaker is working with European authorities to introduce its Navigation Guided Pilot system next year. This development comes amid regulatory challenges for Tesla (NASDAQ: TSLA), which has dropped the Full Self-Driving name in Europe following pushback from German authorities regarding potential customer misconceptions about the system's capabilities. https://www.openbell.ai/news/CYN:1791803327307 2026-10-12T11:08:47.307Z daily 0.9 https://cdn.brandfetch.io/CYN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Cyngn Unveils Commercial Program DriveMod EasyLaunch To Facilitate Manufacturer And Warehouse Deployment Of Autonomous Material Handling Cyngn has launched the EasyLaunch program, allowing qualifying customers to automate material movement using its DriveMod Autonomous Tugger through a monthly subscription model, eliminating the need for upfront capital and long-term commitments. The program is designed for repetitive indoor applications and can be deployed within weeks, with Cyngn managing the vehicle deployment and configuration. This initiative aims to simplify the adoption of industrial autonomy by reducing costs and implementation complexity. https://www.openbell.ai/news/ZBIO:1791803253828 2026-10-12T11:07:33.828Z daily 0.9 https://cdn.brandfetch.io/ZBIO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Zenas BioPharma Presents New Obexelimab Data In Immunoglobulin G4-Related Disease At 6th International Symposium On IgG4-Related Disease Zenas BioPharma presented new data on obexelimab for immunoglobulin G4-related disease (IgG4-RD) at the 6th International Symposium on IgG4-RD. The Phase 3 INDIGO open-label extension showed a 93% probability of remaining flare-free over 12 months and significantly reduced glucocorticoid toxicity compared to placebo. Additionally, initial findings from a sub-study indicated strong vaccine responses during a treatment-free window, with 86% of participants achieving seroimmunity to influenza and 100% to COVID-19. https://www.openbell.ai/news/GOOGL:1791803181907 2026-10-12T11:06:21.907Z daily 0.9 https://cdn.brandfetch.io/GOOGL/w/400/h/400?c=1idopYfmtR7ZKg8QMud Cantor Fitzgerald Reiterates Overweight on Alphabet, Maintains $420 Price Target Cantor Fitzgerald analyst Deepak Mathivanan has reiterated an Overweight rating on Alphabet (NASDAQ: GOOGL) and maintained a price target of $420 for the stock. This endorsement suggests confidence in the company's future performance. https://www.openbell.ai/news/PODD:1791803181524 2026-10-12T11:06:21.524Z daily 0.9 https://cdn.brandfetch.io/PODD/w/400/h/400?c=1idopYfmtR7ZKg8QMud Insulet Announces U.S. Launch Of Omnipod Discover Diabetes Data Platform For Omnipod 5 Users openbell Financial News https://www.openbell.ai/news/INV:1791803147420 2026-10-12T11:05:47.420Z daily 0.9 https://cdn.brandfetch.io/INV/w/400/h/400?c=1idopYfmtR7ZKg8QMud Innventure’s Accelsius Announces Multi-Megawatt Upgrade To Austin Liquid Cooling Test Lab, 18,000-Square-Foot Expansion In January openbell Financial News https://www.openbell.ai/news/RDW:1791803105840 2026-10-12T11:05:05.840Z daily 0.9 https://cdn.brandfetch.io/RDW/w/400/h/400?c=1idopYfmtR7ZKg8QMud Redwire Says Final Pair Of ROSA Solar Array Wings For International Space Station To Launch On SpaceX CRS-35 openbell Financial News https://www.openbell.ai/news/TRAX:1791803089059 2026-10-12T11:04:49.059Z daily 0.9 https://cdn.brandfetch.io/TRAX/w/400/h/400?c=1idopYfmtR7ZKg8QMud First Tracks Biotherapeutics' ANB033 Demonstrates Statistically Significant Histologic And Symptom Benefits In Phase 1b Celiac Disease Trial First Tracks Biotherapeutics, Inc. (NASDAQ: TRAX) reported positive results from its Phase 1b trial of ANB033 for celiac disease, demonstrating statistically significant benefits in both histologic and symptom endpoints compared to placebo. The LS mean change in Vh:Cd ratio was -0.17 for ANB033 versus -0.66 for placebo, with a placebo-adjusted delta of +0.49 (p=0.009). Additionally, ANB033 prevented an increase in symptoms during the gluten challenge, showing a lower CDSD score from the first day. The treatment was well tolerated with no safety concerns reported to date. https://www.openbell.ai/news/BKNG:1791803051521 2026-10-12T11:04:11.521Z daily 0.9 https://cdn.brandfetch.io/BKNG/w/400/h/400?c=1idopYfmtR7ZKg8QMud Cantor Fitzgerald Maintains Neutral on Booking Holdings, Lowers Price Target to $170 Cantor Fitzgerald analyst Deepak Mathivanan has maintained a Neutral rating on Booking Holdings (NASDAQ: BKNG) and has lowered the price target from $220 to $170. https://www.openbell.ai/news/ANIP:1791802997676 2026-10-12T11:03:17.676Z daily 0.9 https://cdn.brandfetch.io/ANIP/w/400/h/400?c=1idopYfmtR7ZKg8QMud ANI Pharmaceuticals Says Phase 4 ILUVIEN Trial In Chronic Posterior Uveitis Met Co-Primary Endpoints, Results Maintained At 24 Months openbell Financial News https://www.openbell.ai/news/BMY:1791802992458 2026-10-12T11:03:12.458Z daily 0.9 https://cdn.brandfetch.io/BMY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Bristol Myers Squibb Announces Topline Results From Unit RayzeBio's Planned Interim Analysis Of ACTION-1 Trial; RYZ101 Study Met Primary Endpoint With Statistically Significant And Clinically Meaningful Improvement In Progression-Free Survival By Blinded Independent Central Review, And Safety Results Consistent With Known Safety Profile Bristol Myers Squibb (NYSE: BMY) announced positive topline results from the interim analysis of the ACTION-1 trial, indicating that RYZ101 (225Ac-DOTATATE) achieved a statistically significant improvement in progression-free survival for patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The study's safety results were consistent with the known safety profile of RYZ101. The FDA had previously granted RYZ101 Orphan Drug Designation for GEP-NETs, and the company plans to engage with the FDA regarding regulatory submission following these results. https://www.openbell.ai/news/GRML:1791802979291 2026-10-12T11:02:59.291Z daily 0.9 https://cdn.brandfetch.io/GRML/w/400/h/400?c=1idopYfmtR7ZKg8QMud Greenland Mines Highlights EU Strategic Project Designation For Neo's Silmet 2.0 Rare Earth Development Greenland Mines Ltd (NASDAQ: GRML) announced that the European Commission has designated Neo Performance Materials Inc.'s Silmet 2.0 development plan as one of 46 new Strategic Projects under the EU's Critical Raw Materials Act. This initiative aims to enhance the infrastructure and production processes at Neo's rare earth separation facility in Estonia, thereby supporting the diversification of Europe's critical-mineral supply chains. Neo, a strategic shareholder in Greenland Mines, holds offtake rights for up to 60% of future Sarfartoq ore production. https://www.openbell.ai/news/IONQ:1791802948568 2026-10-12T11:02:28.568Z daily 0.9 https://cdn.brandfetch.io/IONQ/w/400/h/400?c=1idopYfmtR7ZKg8QMud IonQ Struck All-Stock Deal To Acquire Cybersecurity Firm Elisity In Transaction Valued At Up To $1.3B, WSJ Reported openbell Financial News https://www.openbell.ai/news/IRIX:1791802903038 2026-10-12T11:01:43.038Z daily 0.9 https://cdn.brandfetch.io/IRIX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Iridex Announces Publication Of 2-Yr Clinical Study Demonstrating Favorable Outcomes With TLT Using MicroPulse Technology In Patients With Primary Glaucoma Iridex Corporation (NASDAQ: IRIX) has announced the publication of a two-year clinical study showing favorable outcomes for transscleral laser therapy (TLT) using its MicroPulse Technology in patients with varying stages of primary glaucoma. This development highlights Iridex's position as a leader in innovative laser-based medical systems for treating glaucoma. https://www.openbell.ai/news/TSLA:1791802814454 2026-10-12T11:00:14.454Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/12/Tesla-Cybercab-Automobile-At-The-2025-Ca.jpg?width=250&height=187 Kimbal Musk Says Tesla Cybercab Is ‘Amazing to Use’ as Driverless Fleet Explodes in Austin and Raises Stakes for Elon Musk’s Robotaxi Bet Tesla Inc. (NASDAQ: TSLA) has launched its Cybercab in Austin, with over 300 units now in operation, marking an eightfold increase in just 30 days. The Cybercab, a fully autonomous vehicle without a steering wheel or pedals, aligns with Tesla's goal of expanding its driverless fleet, which also includes Model Y vehicles. Kimbal Musk praised the Cybercab's functionality, while the company aims to accelerate production, claiming it operates more than five times faster than conventional methods. However, Tesla faces regulatory scrutiny regarding the vehicle's certification under U.S. safety rules. https://www.openbell.ai/news/PCVX:1791802646705 2026-10-12T10:57:26.705Z daily 0.9 https://cdn.brandfetch.io/PCVX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Cantor Fitzgerald Reiterates Overweight on Vaxcyte, Announces $120 Price Target Cantor Fitzgerald analyst Carter Gould has reiterated an Overweight rating on Vaxcyte (NASDAQ: PCVX) and set a price target of $120 for the company's stock. This endorsement reflects confidence in Vaxcyte's potential performance in the market. https://www.openbell.ai/news/BMY:1791802312798 2026-10-12T10:51:52.798Z daily 0.9 https://cdn.brandfetch.io/BMY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Bristol Myers Squibb's Admilparant Meets Phase 3 Primary Endpoint in Idiopathic Pulmonary Fibrosis Trial Bristol Myers Squibb (NYSE: BMY) announced that its drug admilparant met the primary endpoint in the Phase 3 ALOFT-IPF trial for idiopathic pulmonary fibrosis, showing a statistically significant improvement in forced vital capacity (FVC) at the 60 mg dose compared to placebo. The drug also exhibited a favorable safety and tolerability profile, with low discontinuation rates due to adverse events. The company plans to conduct a comprehensive evaluation of the trial data and engage with health authorities for regulatory submissions, while results from an ongoing trial in progressive pulmonary fibrosis are expected in early 2027. https://www.openbell.ai/news/UCO:1791802310926 2026-10-12T10:51:50.926Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/12/US-and-Iran-flags-on-a-cracked-backgroun.jpg?width=250&height=187 Iran Was ‘Taking It Easy’ on Trump, Says Analyst — Fresh Tanker Strikes Near Oman Raise Fears the War Could Trigger a Bigger Oil Shock Brett Erickson, Managing Principal at Obsidian Risk Advisors, indicated that Iran's recent strikes on vessels in the Gulf of Oman could escalate tensions and potentially disrupt oil supply, suggesting that the U.S. should reconsider its involvement in the conflict. The UKMTO reported that two vessels, including the 'Petro Dolphin,' were struck, leading to significant damage and the evacuation of crew members, with two Indian mariners reported missing. In response to these developments, West Texas Intermediate crude futures rose by 1.08% to $92.82, while Brent futures increased by 1.31% to $106.09. https://www.openbell.ai/news/BLCO:1791802124009 2026-10-12T10:48:44.009Z daily 0.9 https://cdn.brandfetch.io/BLCO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Bausch + Lomb Appoints Chairman Thomas J. Appio As Interim CEO, Effective Immediately; Company And Its Parent Bausch Health Expect To Raise FY26 Adjusted EBITDA Guidance, Excluding Acquired IPR&D Bausch + Lomb has appointed Thomas J. Appio as interim CEO, effective immediately, following the mutual agreement for Brent Saunders to depart the company. The company and its parent, Bausch Health, expect to raise their full-year 2026 adjusted EBITDA guidance, excluding acquired IPR&D, based on preliminary third-quarter results. Appio, who has been with Bausch + Lomb since 2010 and served as CEO of Bausch Health since 2022, is expected to leverage his experience to lead the company’s next phase of growth. https://www.openbell.ai/news/ASTS:1791802070236 2026-10-12T10:47:50.236Z daily 0.9 https://cdn.brandfetch.io/ASTS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Deutsche Bank Upgrades AST SpaceMobile to Buy, Maintains Price Target to $93 Deutsche Bank analyst Bryan Kraft has upgraded AST SpaceMobile (NASDAQ: ASTS) from a Hold rating to a Buy rating. The price target for the stock remains unchanged at $93. https://www.openbell.ai/news/SPCX:1791801654838 2026-10-12T10:40:54.838Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/12/Hawthorne--United-States---Jul-22--2022-.jpg?width=250&height=187 Elon Musk's SpaceX Could Shake Up US Wireless Market — And Wall Street Sees a Surprise Winner SpaceX has agreed to acquire a nationwide low-band wireless spectrum portfolio from Grain Management for approximately $8 billion, which could enhance Starlink's mobile connectivity and allow it to compete with major U.S. wireless carriers. Analysts suggest this acquisition may create new opportunities for U.S. tower operators, potentially increasing their recurring revenue by 10% to 15%. SpaceX's stock was up 0.62% to $163.58 during premarket trading following the announcement.